Increasing COVID-19 Trials to Provide Opportunity for China Monoclonal Antibodies Market

China monoclonal antibodies market is estimated to grow at a CAGR of nearly 9.2% during the forecast period. An increasing monoclonal antibody COVID-19 trials are offering scope for market growth. For instance, in June 2020, Chinese scientists introduced a phase I trial for the first neutralizing COVID-19 antibody treatment globally. This therapy has shown a promise in stopping the growth of novel coronavirus in animal testing, however, its effectiveness in humans’ rests to be seen. CB6 antibody functions by intervening with the attaching process between the Angiotensin-converting enzyme 2 (ACE2) receptor and the novel coronavirus, thereby blocks the virus from infecting cells. 

Browse the full report description of "China Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Source (Murine, Chimeric, Human, and Humanized), By Application (Cancer, Infectious Diseases, Auto-Immune Diseases, Inflammatory Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/china-monoclonal-antibodies-market

By February 2020, two antibodies had discovered by researchers, CB6 and CA1, that have the potential viral neutralizing capability in vitro. Further, in July 2020, Junshi Biosciences declared the Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection (JS016). This therapy is developed along with the Institute of Microbiology, Chinese Academy of Sciences (IMCAS). It is the first COVID-19 neutralizing antibody that is entering clinical trials in the country. During the second quarter of 2020, JS016 also entered clinical trials in the US.

Scope of the China Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Source and Application
• Competitive Landscape- AstraZeneca plc, Pfizer Inc., Innovent Biologics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Amgen Inc

Recent Strategic Initiatives in the China Monoclonal Antibodies Market

• In December 2019, AstraZeneca declared that NMPA has granted marketing authorization for Imfinzi (durvalumab) to treat patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). This approval represents the company’s long-standing commitment to improve the health outcomes of lung cancer patients in China. 
• In October 2019, Amgen declared a partnership with BeiGene that will further widen Amgen's strategies to enhance the presence of its oncology products in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. Additionally, this acquisition will also support Amgen for the commercialization of its non-oncology product portfolio in China. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

China Cancer Monoclonal Antibodies Market-Segmentation

By Source

• Murine
• Chimeric
• Human
• Humanized

By Application

• Cancer
• Infectious Diseases
• Auto-Immune Diseases
• Inflammatory Diseases
• Others

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/china-monoclonal-antibodies-market